communicating research-related risk p. pearl o’rourke, m.d. partners healthcare boston, ma
TRANSCRIPT
![Page 1: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/1.jpg)
Communicating Research-Related Risk
P. Pearl O’Rourke, M.D.
Partners HealthCare
Boston, MA
![Page 2: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/2.jpg)
Please note…
Benefit may make harms more tolerated, but benefit does NOT erase harm
HARM BENEFIT
![Page 3: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/3.jpg)
To Discuss
• The duty to warn
• Harms and the risks in research
• How we communicate the risk of harm/s
• How what we communicate is ingested
![Page 4: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/4.jpg)
What is Harm?
• Noun– Aggravation, balefulness, damage, damnum,
deadliness, detriment, disablement, evil, hurt, hurtfulness, ill-consequence, ill-treatment, impairment, injury, malignancy, malignity, mischief, misfortune, noxiousness, perniciousness, ruin, scathe, scourge, virulence
http://legal-dictionary.thefreedictionary.com/harm
![Page 5: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/5.jpg)
What is Risk?
• The potential that a specific action or activity (including inaction) will lead to a harm (an undesirable outcome).
• ‘Risk’ is often used to describe harm.
• Almost any human endeavor carries some risk, but some are much more risky than others.
![Page 6: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/6.jpg)
The Risk of Daily Life
Drove to airport – Boston trafficRisks: Car accident Mental anguish
Airport SecurityRisks: Loss of privacy Embarrassment
Airline flightRisks: Crash Airline food Deep vein thrombosis
![Page 7: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/7.jpg)
To Discuss
• The duty to warn
• Harms and the risks in research
• How we communicate the risk of harm/s
• How what we communicate is ingested
• Room for improvement
![Page 8: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/8.jpg)
When we think we have a Duty to Warn
![Page 9: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/9.jpg)
Why we warn
• To provide information so that an individual can make an informed decision– Ideally to protect themselves– Avoid mishap (harm)
• Legal protection (CYA)– Or so we think
![Page 10: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/10.jpg)
Duty to Warn
CAUTION
Research Recruitment
![Page 11: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/11.jpg)
To Discuss
• The duty to warn
• Harms and the risks in research
• How we communicate the risk of harm/s
• How what we communicate is ingested
• Room for improvement
![Page 12: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/12.jpg)
Who can be Harmed in Research?
• The individual
• Family members
• Community
![Page 13: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/13.jpg)
What are Research Harms?
• Inconvenience– Parking– Getting to the site
• Physical– Discomfort– Downright pain– A variety of symptoms
• Rash• Diarrhea
– Loss of life or limb
• Psychological– Stress– Embarrassment
• Social – Stigmatization
• Financial– Insurance coverage
• Legal– Now they know you
are a felon
![Page 14: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/14.jpg)
Important Details of the harms
• Severity/seriousness
• Duration
• Reversibility
• Context
• Probability
![Page 15: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/15.jpg)
This is a study of a new agent for the treatment of rheumatoid arthritis. Drug is an immune-modulator.
Potential risks include:
•20% have developed a transient rash
•10% developed serious hypertension that required therapy
•5% developed a serious infection
•0.5% developed a neoplasm (cancer)
![Page 16: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/16.jpg)
This is a study of a new agent for the treatment of rheumatoid arthritis. Drug is an immune-modulator.
Potential risks include:
•20% have developed a transient rash
•10% developed serious hypertension that required therapy
•5% developed a serious infection
•0.5% developed a neoplasm (cancer)
What if: Your mother has RA – and you have slight morning stiffness in one knee.
You have bad pain in both knees and ankles that is reasonably controlled with NSAIDs
You cannot walk up stairs
You need a walker for ambulation
![Page 17: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/17.jpg)
Important Details of the harms
Probability
• Almost always – in fact anticipated
• Frequent, common, often,
• Occasional, in a some cases,
• Rare, very rare
• Has never happened but is theoretically possible
![Page 18: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/18.jpg)
To Discuss
• Daily acceptance of risk of harm
• The duty to warn
• Harms and the risks in research
• How we communicate the risk of harm/s
• How what we communicate is ingested
![Page 19: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/19.jpg)
The ‘Ideal”
• Unbiased presentation
• Straight-forward, simple language– That this is research– What the participant will be expected to do– Potential benefits– Potential harms – and risk for same
• Clearly state that it is not possible to anticipate or list all risks – you will include the most likely
• Provide meaningful ‘probability’
![Page 20: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/20.jpg)
Simple Language
• Goal = “Just right”
• Avoid un-necessary big words– The risks include induration and ecchymosis at the
injection site and rare events of asystole have been reported
• You might get a bruise and die.
• Avoid un-necessary small words– The risks include some small red marks or bumps on
your skin that may or may not be itchy.• You might get a rash
![Page 21: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/21.jpg)
Benefits
• Avoid over-promise
• Example:This study, called GROUP (Get Rid of Your
Pain) focuses on a new therapy for cluster headaches – specifically for patients who have failed all other therapies and have no where else to turn.
We are extremely hopeful that this new drug will be ‘the answer’ for anyone suffering from CH.
![Page 22: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/22.jpg)
Benefits
• Avoid over-promise
• Example:This study, called GROUP (Get Rid of Your
Pain) focuses on a new therapy for cluster headaches – specifically for patients who have failed all other therapies and have no where else to turn.
We are extremely hopeful that this new drug will be ‘the answer’ for anyone suffering from CH.
![Page 23: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/23.jpg)
Of the known-risks – which to include?
• Everything
• Only the likely ones
• All serious harms – Even if only hypothetical
Consider some examples…
![Page 24: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/24.jpg)
Survey research
• Research:– 4 page survey regarding cheating
behavior
• Risks:– Sensitive questions may cause stress– Loss of privacy– Paper cut from handling the survey
pages– Infection of the aforementioned paper
cut
![Page 25: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/25.jpg)
Research Cardiac Catheterization
• Risks:– May cause a serious arrhythmia
• Resuscitation could be successful• Resuscitation could be unsuccessful
– Catheter may puncture the heart and cause• Bleeding into the pericardial sac which
– Can require emergency drainage of the blood by insertion of another catheter through the chest wall into the heart
– Can require emergency surgery
– Catheter could break and cause damage to any organ in the body
• Stroke, heart attack, kidney damage, liver damage etc.
![Page 26: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/26.jpg)
Research Cardiac Catheterization
• Risks:– Catheter may damage a heart valve which
• May require cardiac surgery
– Problems at the catheter insertion site (femoral artery)
• Bleeding• Rupture of the artery that
– Could cause lack of blood flow to the leg and if artery cannot be fixed – loss of the leg
– Could require surgical repair
![Page 27: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/27.jpg)
Research Cardiac Catheterization
• Risks:– The dye can cause:
• Allergic reactions– Allergic reactions can kill
• Worsen limited kidney failure
– Pressure sore from lying on the cold radiology table
![Page 28: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/28.jpg)
Clear communication of probability
• Recommendations– Do not use vague descriptive words (e.g. rare,
common)– Use multiple formats (e.g. numbers, graphs)– Show pictorial representations as possible– Present comparisons with a common denominator– Use absolute as opposed to relative risks– Avoid small percentages (0.06%); use 6 per 10,000
instead– Individualize estimates if possible
Aliment Pharmacol Ther 2011;33:23-32
![Page 29: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/29.jpg)
Words vs Numbers
• Numbers preferred over words– 46.6% preferred numbers– 20.6% preferred verbal descriptions– 32.8% had no preference
» J Empir res Hum Res Ethics 2009;4:17-26
![Page 30: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/30.jpg)
Words vs numbers
• European Commission recommended verbal descriptors
Aliment Pharmacol Ther 2011;33:23-32
Eur. Comm.
Common 1-10%
Rare 0.01-0.1%
Very Rare <0.01%
![Page 31: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/31.jpg)
Words vs numbers
• European Commission recommended verbal descriptors
Aliment Pharmacol Ther 2011;33:23-32
Eur. Comm.
Students
Common 1-10% 45%
Rare 0.01-0.1% 8%
Very Rare <0.01% 4%
![Page 32: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/32.jpg)
So – everyone wants numbers Do they know what they mean?
• 50% of people – could NOT convert 1% to 10/1000
• 80% of subjects– unable to convert 1/1000 to 0.1%
• Difficulty figuring out if 1 in 27 is higher or lower than 1 in 37– N.b., Medical students did not fare any better
Aliment Pharmacol Ther 2011;33:23-32
![Page 33: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/33.jpg)
Do not add confusion
Research
Risks
Research
Risks
Framing Bias
![Page 34: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/34.jpg)
The potential benefit of this drug is that it will decrease your risk of developing kidney failure by 75%. (relative risk)
FYI: The potential effect on your absolute risk of developing kidney failure:
Existing risk Potential risk
0.5% 0.125%
5.0% 1.25%
50% 12.5%
![Page 35: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/35.jpg)
Framing Bias
• Hypothetical cholesterol lowering drug– Effect represented two ways:
• 34% relative risk reduction of MI• 1.4% absolute risk reduction
– Twice as many people enrolled when presented as a 34% relative risk reduction
• Best able to figure out benefit when given relative risk reduction AND baseline risk
Aliment Pharmacol Ther 2011;33:23-32
![Page 36: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/36.jpg)
Framing Bias
• Study: surgery or radiation for lung cancer– When presented as surgical survival of 80%
• 18% opted for radiation • 82% opted for surgery
– When presented as surgical mortality of 20%• 44% opted for radiation• 56% opted for surgery
McNeil et al
![Page 37: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/37.jpg)
This study, called GROUP (Get Rid of Your Pain) focuses on a new therapy for cluster headaches – specifically for patients who have failed all other therapies and have no where else to turn.
We are extremely hopeful that this new drug will be ‘the answer’ for anyone suffering from CH.
This new drug has already been studied at other institutions and some side effects have been reported. These include:
•Most people developed a transient rash
•About 25% had mild nausea
•And only a few had double vision and vertigo lasting several days
Consider
![Page 38: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/38.jpg)
This study, called GROUP (Get Rid of Your Pain) focuses on a new therapy for cluster headaches – specifically for patients who have failed all other therapies and have no where else to turn.
We are extremely hopeful that this new drug will be ‘the answer’ for anyone suffering from CH.
This new drug has already been studied at other institutions and some side effects have been reported. These include:
•Most people developed a transient rash
•About 25% had mild nausea
•And only a few had double vision and vertigo lasting several days
We do not expect that any of these potential side effects will be a problem for you, and we think that with careful dose monitoring serious side effects can be avoided.
Consider
![Page 39: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/39.jpg)
To Discuss
• The duty to warn
• Harms and the risks in research
• How we communicate the risk of harm/s
• How what we communicate is ingested
![Page 40: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/40.jpg)
How our info is received
• Too long…too much
• Confusion with words
• Confusion with purpose
• Confusion with understanding risk
• Too often not read
• Too often not remembered
![Page 41: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/41.jpg)
Effect of harm severity
– “Death and pneumonia are rare events”• Assumption that death much less likely than
pneumonia
– “Visual impairment and dry mouth are rare events”
• Students interpreted that as:– Risk of visual impairment: 2.3 +/- 2.7%– Risk of dry mouth: 8.8 +/- 7.7%
IRB: Ethics & Hum Res 2008;30:15-18
![Page 42: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/42.jpg)
Frequency vs belief expectation
• ICF states: 90% of people receiving this drug will have no effect
• “It will be me” – I shall be in the 10%– This is belief expectation
IRB: Ethics & Hum Res 2009;31:1-10
![Page 43: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/43.jpg)
Personalizing Risk
• Early-phase cancer study
• Participants asked to assess chances of long-term benefit– For all cancer participants: 12.6%– For themselves 41.7%
IRB: Ethics & Hum Res 2009;31:1-10
![Page 44: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/44.jpg)
Personalizing Risk
• Early-phase cancer study
• Participants asked to assess chances of long-term benefit– For all cancer participants: 12.6%– For themselves 41.7%
• Those expecting long-term benefit 17 times more likely to enroll
IRB: Ethics & Hum Res 2009;31:1-10
![Page 45: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/45.jpg)
Availability Heuristic
• Research:– 4 page survey regarding cheating behavior
• Risks:– Sensitive questions may cause stress
– Loss of privacy
– Paper cut from handling the survey pages
– Infection of the aforementioned paper cut
![Page 46: Communicating Research-Related Risk P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA](https://reader035.vdocuments.net/reader035/viewer/2022062717/56649e615503460f94b5ca76/html5/thumbnails/46.jpg)
Availability Heuristic
• Research:– 4 page survey regarding cheating behavior
• Risks:– Sensitive questions may cause stress
– Loss of privacy
– Paper cut from handling the survey pages
– Infection of the aforementioned paper cut
My father died from sepsis which started from a small cut in his finger…the risk of this
study is too high for me!
I’m outta here!